Stoke and Biogen Release Zorevunersen Study Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Source: NASDAQ.COM
- Study Results Released: Stoke Therapeutics and Biogen announced the publication of data on the investigational drug Zorevunersen, indicating its potential for disease modification in patients with Dravet syndrome, marking a significant advancement in treatment options.
- Clinical Trial Data: Results from two completed Phase 1/2a trials and ongoing open-label extension studies demonstrated substantial and durable reductions in seizures, along with improvements across multiple cognitive and behavioral measures, indicating long-term efficacy.
- Future Research Outlook: Barry Ticho, Chief Medical Officer of Stoke, stated that Zorevunersen could become the first disease-modifying medicine for Dravet syndrome, with anticipation for the Phase 3 EMPEROR study results expected in mid-2027 to further validate its efficacy.
- Market Reaction: Stoke shares closed at $34.42 on Nasdaq, up 1.89%, reflecting positive market expectations regarding the drug's potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 200.360
Low
143.00
Averages
204.45
High
246.00
Current: 200.360
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Incyte and TG Therapeutics Show Strong Growth Potential
- Incyte's Financial Health: Incyte's JAK inhibitor Jakafi generated $758 million in sales for rare blood cancers, reflecting a 7% year-over-year increase, while its dermatology cream Opzelura achieved $143 million in sales, up 20%, leading to an overall revenue of $1.27 billion, a 21% increase, showcasing the company's robust cash flow and operational efficiency.
- Pipeline Diversification: Incyte's strategic $1.25 billion acquisition of Vega Therapeutics enhances its hematology portfolio, particularly with a promising phase 3 asset for bleeding disorders, thereby enriching its late-stage pipeline and positioning the company for future revenue growth.
- TG Therapeutics Growth Momentum: TG Therapeutics' Briumvi drug generated $194.8 million in sales in Q1 2026, prompting the company to raise its full-year revenue guidance to $925 million, indicating strong market demand in the multiple sclerosis treatment sector.
- Significant Acquisition Potential: With an impressive gross margin of 83% and a 69.5% year-over-year revenue increase to $204.9 million in Q1, TG Therapeutics, alongside a 300% EPS growth, emerges as a prime acquisition target for major pharmaceutical companies looking to expand their neurology franchises amid a competitive landscape.
See More
Incyte Expands Pipeline Through Acquisitions, Anticipates New Drug Approvals
- Pipeline Expansion: Incyte has successfully expanded its pipeline through the acquisition of Vega Therapeutics, anticipating four new drug approvals by 2027, which will further enhance its competitive position in oncology and immunology markets.
- Strong Financial Performance: Incyte reported total revenue of $1.27 billion in Q1, a 21% year-over-year increase, with Jakafi sales reaching $758 million and Opzelura at $143 million, demonstrating robust market demand in rare blood cancers and dermatological treatments.
- Improved Profitability: Incyte's adjusted EPS was $1.81, exceeding analysts' expectations of $1.34, reflecting the management team's efficiency in capital utilization, with a return on equity exceeding 30%.
- Growth Potential for TG Therapeutics: TG Therapeutics' Briumvi drug generated $194.8 million in sales in Q1, prompting management to raise full-year revenue guidance to $925 million, indicating strong growth potential in the multiple sclerosis treatment market.
See More
Biogen Acquires RayThera to Strengthen Immunology Business
- Revenue Growth Challenges: Biogen's multiple sclerosis (MS) drug sales have significantly declined due to patent expirations, with Tecfidera's sales dropping from $4.4 billion in 2019 to $1.4 billion in 2022, and total MS drug revenue only reaching $4 billion in the latest fiscal year, highlighting increasing market competition pressures.
- Strategic Acquisition Moves: In 2023, Biogen acquired Apellis Pharmaceuticals, gaining access to two commercialized drugs that generated $689 million in sales last year, further strengthening its position in the immunology sector and laying the groundwork for future growth.
- New Acquisition Prospects: Biogen's acquisition of RayThera for up to $1 billion, despite the lack of public details on its candidates, suggests potential anti-inflammatory assets targeting various immune-mediated diseases, which could yield substantial revenue potential given the global immunology market's size exceeding $112 billion.
- Signs of Business Stabilization: After four years of declining earnings, Biogen's CEO indicated that 2023 marks a turnaround, with first-quarter sales of new drugs increasing by 12% to $850 million, demonstrating a recovery in the emerging neurology drug sector and the potential for sustained growth ahead.
See More
Biogen Acquires RayThera for $1 Billion to Boost Immunology Business
- MS Business Update: Biogen's multiple sclerosis drugs generated $4 billion in revenue in 2022, down from $4.4 billion in 2019, highlighting the competitive pressures from patent expirations that have forced the company to adjust its strategy to maintain market position.
- Growth Plan Implementation: In 2023, Biogen achieved a 12% increase in sales to $850 million, primarily driven by a focus on growth products like Leqembi for Alzheimer's disease, marking a turnaround after four years of declining earnings.
- Acquisition Strategy: Biogen's acquisition of Apellis Pharmaceuticals in 2023 brought in two commercialized drugs with $689 million in sales, further solidifying its position in the immunology market and laying the groundwork for future growth.
- RayThera Acquisition Potential: Biogen's acquisition of RayThera for up to $1 billion, despite limited product details, suggests a portfolio of multiple anti-inflammatory assets that could target various immune-mediated conditions, indicating significant revenue potential and aligning with the company's strategic goal to expand its immunology business.
See More
Biogen's Diversified Strategy and Investment Opportunities
- Financial Forecast Adjustment: Biogen expects approximately $164 million in non-recurring charges in Q2 2026, which will reduce adjusted earnings per share by about $0.95, indicating significant expenditures in research and development and milestone payments.
- Investor Focus on Data Release: Investors are awaiting mid-stage data for Biogen's Alzheimer’s drug diranersen, set to be announced mid-July at a London conference, which could impact the company's future stock price trajectory and market confidence.
- Acquisition Enhances Pipeline: Biogen has agreed to acquire RayThera Inc. for up to $1 billion to bolster its immunology pipeline, with the deal expected to close in Q3, further advancing the company's research in small-molecule anti-inflammatory assets.
- Market Sentiment Shift: Retail sentiment around BIIB stock shifted from 'neutral' to 'bullish' over the past 24 hours, reflecting optimistic expectations for Biogen's future performance, with the stock gaining 23% year-to-date.
See More
Investment Opportunities in Biotech Stocks
- Biotech Risk and Reward: In the biotech sector, investors face high-risk, high-reward scenarios, exemplified by Sarepta (SRPT) which saw a 20% drop following a failed clinical trial, highlighting the volatility and uncertainty in this industry.
- ETF Investment Strategy: Despite Sarepta's poor performance, the Bio-Tech ETF (XBI) shows a strong upward trend, suggesting investors should buy on pullbacks to capitalize on its potential upside, with a current target price of $150.
- Short-term Opportunity in Biogen: Biogen (BIIB) is making progress in treating autoimmune kidney diseases and Alzheimer's, with its stock recently breaking out of an ascending triangle, targeting $240 in the short term, while support is seen just above $200, offering a favorable risk/reward setup.
- Long-term Trend Analysis: The weekly chart for Biogen indicates a breakout from a downtrend since its 2021 peak and has surpassed the 200-week moving average; if the price breaks above $225, it will confirm longer-term upside targets of $300, indicating strong market potential.
See More
Incyte and TG Therapeutics Show Strong Growth Potential
- Incyte's Financial Health: Incyte's JAK inhibitor Jakafi generated $758 million in sales for rare blood cancers, reflecting a 7% year-over-year increase, while its dermatology cream Opzelura achieved $143 million in sales, up 20%, leading to an overall revenue of $1.27 billion, a 21% increase, showcasing the company's robust cash flow and operational efficiency.
- Pipeline Diversification: Incyte's strategic $1.25 billion acquisition of Vega Therapeutics enhances its hematology portfolio, particularly with a promising phase 3 asset for bleeding disorders, thereby enriching its late-stage pipeline and positioning the company for future revenue growth.
- TG Therapeutics Growth Momentum: TG Therapeutics' Briumvi drug generated $194.8 million in sales in Q1 2026, prompting the company to raise its full-year revenue guidance to $925 million, indicating strong market demand in the multiple sclerosis treatment sector.
- Significant Acquisition Potential: With an impressive gross margin of 83% and a 69.5% year-over-year revenue increase to $204.9 million in Q1, TG Therapeutics, alongside a 300% EPS growth, emerges as a prime acquisition target for major pharmaceutical companies looking to expand their neurology franchises amid a competitive landscape.
See More
Incyte Expands Pipeline Through Acquisitions, Anticipates New Drug Approvals
- Pipeline Expansion: Incyte has successfully expanded its pipeline through the acquisition of Vega Therapeutics, anticipating four new drug approvals by 2027, which will further enhance its competitive position in oncology and immunology markets.
- Strong Financial Performance: Incyte reported total revenue of $1.27 billion in Q1, a 21% year-over-year increase, with Jakafi sales reaching $758 million and Opzelura at $143 million, demonstrating robust market demand in rare blood cancers and dermatological treatments.
- Improved Profitability: Incyte's adjusted EPS was $1.81, exceeding analysts' expectations of $1.34, reflecting the management team's efficiency in capital utilization, with a return on equity exceeding 30%.
- Growth Potential for TG Therapeutics: TG Therapeutics' Briumvi drug generated $194.8 million in sales in Q1, prompting management to raise full-year revenue guidance to $925 million, indicating strong growth potential in the multiple sclerosis treatment market.
See More
Biogen Acquires RayThera to Strengthen Immunology Business
- Revenue Growth Challenges: Biogen's multiple sclerosis (MS) drug sales have significantly declined due to patent expirations, with Tecfidera's sales dropping from $4.4 billion in 2019 to $1.4 billion in 2022, and total MS drug revenue only reaching $4 billion in the latest fiscal year, highlighting increasing market competition pressures.
- Strategic Acquisition Moves: In 2023, Biogen acquired Apellis Pharmaceuticals, gaining access to two commercialized drugs that generated $689 million in sales last year, further strengthening its position in the immunology sector and laying the groundwork for future growth.
- New Acquisition Prospects: Biogen's acquisition of RayThera for up to $1 billion, despite the lack of public details on its candidates, suggests potential anti-inflammatory assets targeting various immune-mediated diseases, which could yield substantial revenue potential given the global immunology market's size exceeding $112 billion.
- Signs of Business Stabilization: After four years of declining earnings, Biogen's CEO indicated that 2023 marks a turnaround, with first-quarter sales of new drugs increasing by 12% to $850 million, demonstrating a recovery in the emerging neurology drug sector and the potential for sustained growth ahead.
See More
Biogen Acquires RayThera for $1 Billion to Boost Immunology Business
- MS Business Update: Biogen's multiple sclerosis drugs generated $4 billion in revenue in 2022, down from $4.4 billion in 2019, highlighting the competitive pressures from patent expirations that have forced the company to adjust its strategy to maintain market position.
- Growth Plan Implementation: In 2023, Biogen achieved a 12% increase in sales to $850 million, primarily driven by a focus on growth products like Leqembi for Alzheimer's disease, marking a turnaround after four years of declining earnings.
- Acquisition Strategy: Biogen's acquisition of Apellis Pharmaceuticals in 2023 brought in two commercialized drugs with $689 million in sales, further solidifying its position in the immunology market and laying the groundwork for future growth.
- RayThera Acquisition Potential: Biogen's acquisition of RayThera for up to $1 billion, despite limited product details, suggests a portfolio of multiple anti-inflammatory assets that could target various immune-mediated conditions, indicating significant revenue potential and aligning with the company's strategic goal to expand its immunology business.
See More
Biogen's Diversified Strategy and Investment Opportunities
- Financial Forecast Adjustment: Biogen expects approximately $164 million in non-recurring charges in Q2 2026, which will reduce adjusted earnings per share by about $0.95, indicating significant expenditures in research and development and milestone payments.
- Investor Focus on Data Release: Investors are awaiting mid-stage data for Biogen's Alzheimer’s drug diranersen, set to be announced mid-July at a London conference, which could impact the company's future stock price trajectory and market confidence.
- Acquisition Enhances Pipeline: Biogen has agreed to acquire RayThera Inc. for up to $1 billion to bolster its immunology pipeline, with the deal expected to close in Q3, further advancing the company's research in small-molecule anti-inflammatory assets.
- Market Sentiment Shift: Retail sentiment around BIIB stock shifted from 'neutral' to 'bullish' over the past 24 hours, reflecting optimistic expectations for Biogen's future performance, with the stock gaining 23% year-to-date.
See More
Investment Opportunities in Biotech Stocks
- Biotech Risk and Reward: In the biotech sector, investors face high-risk, high-reward scenarios, exemplified by Sarepta (SRPT) which saw a 20% drop following a failed clinical trial, highlighting the volatility and uncertainty in this industry.
- ETF Investment Strategy: Despite Sarepta's poor performance, the Bio-Tech ETF (XBI) shows a strong upward trend, suggesting investors should buy on pullbacks to capitalize on its potential upside, with a current target price of $150.
- Short-term Opportunity in Biogen: Biogen (BIIB) is making progress in treating autoimmune kidney diseases and Alzheimer's, with its stock recently breaking out of an ascending triangle, targeting $240 in the short term, while support is seen just above $200, offering a favorable risk/reward setup.
- Long-term Trend Analysis: The weekly chart for Biogen indicates a breakout from a downtrend since its 2021 peak and has surpassed the 200-week moving average; if the price breaks above $225, it will confirm longer-term upside targets of $300, indicating strong market potential.
See More
